Simcere Announces $292 Million Deal for Novel Glioblastoma Treatment

Simcere Pharma of Nanjing  announced a $292 million agreement to develop a proposed Kazia Therapeutics treatment for glioma in Greater China. Paxalisib is a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is disordered in the majority patients with glioblastoma, the most common and most aggressive form of primary brain cancer. Kazia, an Australian company, said paxalisib seemed to be effective in a pivotal Phase II trial among GBM patients, though the trial began less than three months ago. More details.... Stock Symbols: (HK: 2096) (ASX: KZA; NSDQ: KZIA) Share this with colleagues: // //